Have a look at the last investor presentation and listen also to...

Have a look at the last investor presentation and listen also to the investor call. You will find the case study of Germany which will provide the model for building up sales within a country. The double blind results (and FDA!) will help a lot. But it is a matter or working with the distributor to build awareness of the new device. In particular bringing on board medical practitioners (I think they were targeting 20 in Germany by about the end of they year). It will be the well credentialed specialists who are recommending/prescribing Mente as a treatment regime. This is when the sales will roll in, when Mente is the treatment prescribed for Autistic children. Who wouldnt pay $2K to help their child if it was impacting their learning and social interactions??

Earlier on, upon release of the preliminary results, we had a lot of down-rampers on here that were trying to build conspiracy theories around Carrick, neurofeedback therapy etc. What i have been able to glean since (partly from a family member who is a psychologist) is that neurofeedback therapy is a well established treatment protocol. It is not witchcraft. But what Mente brings is treatment in the home which is vastly better for patients - especially autistic children to be able to stay in their familiar family home with parents rather than into a strange hospital full of strangers.

Once doctors are prescribing this, NTI is going to be big, but it wont happen overnight. it will take time, country by country to work with doctors. Getting out to scientific conferences for the relevant professionals, marketing, FDA. It will all help. Once numbers of units in each country build then reimbursements will become available, and at that stage, it might be time for a few rockets to be posted!!!